These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 24692700)

  • 21. Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
    Honma Y; Shimizu S; Takehara T; Harada M
    J Gastroenterol; 2014 Mar; 49(3):517-26. PubMed ID: 23543326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
    Newell P; Toffanin S; Villanueva A; Chiang DY; Minguez B; Cabellos L; Savic R; Hoshida Y; Lim KH; Melgar-Lesmes P; Yea S; Peix J; Deniz K; Fiel MI; Thung S; Alsinet C; Tovar V; Mazzaferro V; Bruix J; Roayaie S; Schwartz M; Friedman SL; Llovet JM
    J Hepatol; 2009 Oct; 51(4):725-33. PubMed ID: 19665249
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
    Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
    Kahraman DC; Kahraman T; Cetin-Atalay R
    Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G; Wang M; Carr BI
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
    Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
    Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma.
    Chen L; Wang L; Han Z; Qin P; Niu G; Du J
    Tohoku J Exp Med; 2024 Mar; 262(3):173-180. PubMed ID: 38123304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
    Kim MN; Lee SM; Kim JS; Hwang SG
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH; Chen MC; Wang JC; Tsai AC; Chen CS; Liou JP; Pan SL; Teng CM
    Clin Cancer Res; 2014 Mar; 20(5):1274-1287. PubMed ID: 24520095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
    Kim H; Lim HY
    J Korean Med Sci; 2011 Dec; 26(12):1563-8. PubMed ID: 22147992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.